Nordea Investment Management Boosts Stake in Akebia Therapeutics

The investment firm acquired over 750,000 shares of the biopharmaceutical company in Q4 2025.

Mar. 29, 2026 at 9:10am

Got story updates? Submit your updates here. ›

Nordea Investment Management AB acquired a new position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 752,106 shares of the biopharmaceutical company's stock, valued at approximately $1,215,000.

Why it matters

Akebia Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for patients with kidney disease. Nordea's investment in the company signals potential institutional confidence in Akebia's pipeline and future growth prospects.

The details

Nordea Investment Management AB now owns 0.28% of Akebia Therapeutics as of its most recent SEC filing. Other major institutional investors, including UBS Group AG, MPM Bioimpact LLC, and Invesco Ltd., have also increased their stakes in the company over the past year.

  • Nordea acquired the new position in Akebia Therapeutics during the fourth quarter of 2025.
  • Akebia Therapeutics' stock opened at $1.34 on Friday, March 29, 2026.

The players

Nordea Investment Management AB

A Swedish investment management firm that acquired a new position in Akebia Therapeutics in Q4 2025.

Akebia Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing therapies for patients with kidney disease.

Got photos? Submit your photos here. ›

The takeaway

Nordea's investment in Akebia Therapeutics suggests growing institutional confidence in the company's ability to develop successful kidney disease treatments, which could be a positive sign for the stock's future performance.